China's Breakthrough in Cancer Treatment Raises Questions About Global Competition Akeso, a Chinese biopharmaceutical company, recently announced that its immunotherapy drug, ivonescimab, outperformed AstraZeneca's Imfinzi in a head to head phase three trial for biliary tract cancer.
This breakthrough is part of a larger trend of Chinese companies making significant strides in developing innovative treatments.
Biliary tract cancer is particularly deadly, with a five year survival rate of less than 5%.